Nanrilkefusp alfa (SO-C101; SOT101) 是一种融合蛋白，是IL-15和IL-15Rαsushi+结构域的选择性的强效激动剂。Nanrilkefusp alfa 通过诱导记忆性 CD8+T 细胞、自然杀伤细胞、γ/δ T 细胞和自然杀伤 T 细胞的增殖和激活来抑制肿瘤。在各种小鼠肿瘤模型中，Nanrilkefusp alfa 表现出出色的抗黑色素瘤转移活性并抑制肿瘤生长。
| 生物活性 | Nanrilkefusp alfa (SO-C101; SOT101) is fusion protein, is a selective and potent agonist fusion protein ofIL-15andIL-15Rαsushi+domain. Nanrilkefusp alfa inhibits tumor by inducing proliferation and activation of memory CD8+T cells, natural killer (NK) cells, γ/δ T cells and NKT cells. Nanrilkefusp alfa exhibits excellent anti-metastatic activity against melanoma and suppresses tumor growth in various mouse tumor models[1][2]. |
| IC50& Target[1][2] | |
体外研究
(In Vitro) | Nanrilkefusp alfa (0.01-10 nM; 7 d) expands and activates NK cell subtypes from human PBMCs in vitro[1].
Nanrilkefusp alfa (1 nM; 20 h) induces cytotoxic and tumor cell-killing activity of human NK cell subtypes[1].
Nanrilkefusp alfa (0.1, 1, and 10 nM; 3 d and 7 d) induces expression of cytotoxic receptors NKp30, DNAM-1 and NKG2D on human NK cells[1].
|
体内研究
(In Vivo) | Nanrilkefusp alfa (2 mg/kg; s.c.; 4 consecutive days over 2 weeks) decreases the rate of tumor development and growth in metastatic kidney cancer Renca mouse model in dependence on natural killer (NK) and CD8+T cells. And Nanrilkefusp alfa also activates NK and CD8+T cytotoxicity genes in the TC-1 tumor model[1].
Nanrilkefusp alfa (1 mg/kg; i.p.; 4 consecutive days over 2 weeks) with 12.5 mg/kg anti-PD-1 decreases tumor growth of established TRAMP-C2 tumors and expands the populations of CD8+T cells and NK cells, but not T regulatory cells (Tregs). And Nanrilkefusp alfa also mediates inhibition of TRAMP-C2 tumor development depending mainly on NK and CD8+T cells[2].
| Animal Model: | Metastatic kidney cancer Renca mouse model[1] | | Dosage: | 2 mg/kg | | Administration: | Subcutaneous injection; for 4 consecutive days over 2 weeks | | Result: | Decreased the rate of the tumor development.
Decreased the tumor growth of established TC-1 tumors in dependence on NK and CD8+T cells, but not CD4+T cells.
Expanded immune cells in tumor, lymph nodes and spleen and activates NK and CD8+T cytotoxicity genes in TC-1 tumor mouse model. |
| Animal Model: | TRAMP-C2 tumors mouse model[2] | | Dosage: | 1 mg/kg; with or without 12.5 mg/kg anti-PD-1 | | Administration: | Intraperitoneal injection; for 4 consecutive days over 2 weeks | | Result: | Prevented tumor development with anti-PD-1 in the majority of TRAMP-C2 mouse and delays tumor growth after re-challenge.
|
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
